Carisma Therapeutics
NEWS
Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.
Carisma Therapeutics is merging with Sesen Bio to advance Carisma’s cell therapy platform - in particular, its chimeric antigen receptor macrophage (CAR-M) therapies.
Moderna roared through 2021 on the strength of its COVID-19 vaccine and that momentum is continuing in 2022.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
This week multiple companies have announced millions of investment dollars have flooded their coffers to advance research and development of multiple therapies. BioSpace is rounding up the announcements.
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week’s appointments.
AbbVie Ventures, the investment arm of AbbVie, led a $53 million Series A funding round for Carisma Therapeutics and its immunotherapy CAR-Macrophage platform.
CARMA Therapeutics is based on technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out of the laboratory of Saar Gill, assistant professor of Hematology Oncology in the Perelman School of Medicine there.
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
JOBS
IN THE PRESS